- Home
- WGRX vs MAIA Comparison
WGRX vs MAIA Comparison
Compare WGRX & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- MAIA
- Stock Information
- Founded
- WGRX 2022
- MAIA 2018
- Country
- WGRX United States
- MAIA United States
- Employees
- WGRX N/A
- MAIA N/A
- Industry
- WGRX Other Pharmaceuticals
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- MAIA Health Care
- Exchange
- WGRX Nasdaq
- MAIA Nasdaq
- Market Cap
- WGRX 54.8M
- MAIA 56.7M
- IPO Year
- WGRX 2025
- MAIA 2022
- Fundamental
- Price
- WGRX $0.58
- MAIA $1.44
- Analyst Decision
- WGRX
- MAIA
- Analyst Count
- WGRX 0
- MAIA 0
- Target Price
- WGRX N/A
- MAIA N/A
- AVG Volume (30 Days)
- WGRX 1.2M
- MAIA 574.7K
- Earning Date
- WGRX 11-11-2025
- MAIA 11-11-2025
- Dividend Yield
- WGRX N/A
- MAIA N/A
- EPS Growth
- WGRX N/A
- MAIA N/A
- EPS
- WGRX N/A
- MAIA N/A
- Revenue
- WGRX $36,738,599.00
- MAIA N/A
- Revenue This Year
- WGRX N/A
- MAIA N/A
- Revenue Next Year
- WGRX N/A
- MAIA N/A
- P/E Ratio
- WGRX N/A
- MAIA N/A
- Revenue Growth
- WGRX 82384.51
- MAIA N/A
- 52 Week Low
- WGRX $0.56
- MAIA $1.40
- 52 Week High
- WGRX $7.04
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- WGRX 28.88
- MAIA 39.48
- Support Level
- WGRX $0.57
- MAIA $1.65
- Resistance Level
- WGRX $0.67
- MAIA $1.97
- Average True Range (ATR)
- WGRX 0.10
- MAIA 0.11
- MACD
- WGRX -0.03
- MAIA -0.03
- Stochastic Oscillator
- WGRX 2.56
- MAIA 4.46
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.